- Cardiac valvulopathy occurs in patients using cabergoline for long term (Parkinson’s disease) as well as for short term treatment (hyperprolactinemia); perform echocardiography and evaluate cardiovascular function before initiating treatment. Evaluate patient for cardiac valvulopathy if signs or symptoms of cardiac disease including dyspnea, edema, congestive heart failure, or a new cardiac murmur develops
- Periodically reassess cardiac status, and perform echocardiography in patients on long term therapy
- Use lowest effective dose for treatment of hyperprolactinemia, periodically reassess for the need of continuing therapy
- Avoid use in patients with pregnancy-induced hypertension and post partum hypertension, unless potential benefit outweigh the possible risk
- Cabergoline causes orthostatic hypotension, avoid concomitant use with other medications known to lower blood pressure
- Pleural effusion or pulmonary fibrosis occurs in patients using cabergoline for long term, avoid in patients with history of or current signs and symptoms of respiratory or cardiac disorders linked to fibrotic tissue
- Perform chest x-ray if ESR value increases abnormally, as it is associated with pleural effusion/fibrosis, also measure serum creatinine for diagnosis of fibrotic disorder
- Discontinue treatment following diagnosis of pleural effusion or pulmonary fibrosis
- Discontinue on occurrence of pathological gambling, increased libido and hypersexuality
- Periodically monitor patients with hepatic impairment and if possible start with lower doses of cabergoline
- Efficacy beyond 24 months of therapy has not been established
- Cabergoline is not indicated for the inhibition/suppression of physiologic lactation as the use of bromocriptine, another dopamine agonist for this purpose, has been associated with cases of hypertension, stroke, and seizures
Cautions: Use cautiously in
- Hepatic impairment
- Significant valvular disease
Pregnancy Category:B
Breastfeeding: Safety unknown; It suppresses lactation. US FDA considers that due to the potential risk of hypertension, stroke and seizures it should not be indicated to suppress lactation. It may cause headache, dizziness and nausea. Severe adverse effects rarely occurred with the drug. This information is based on LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 06 December 2010). Manufacturer advises to avoid use in women on breastfeeding or planning to breastfeed
Pricing data from www.DrugStore.com in U.S.A.
- Cabergoline 0.5 MG TABS [Bottle] (TEVA PHARMACEUTICALS USA)
8 mg = $285.97
24 mg = $809.95
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
10): Dose adjustments not defined
